Aquarius Surgical Technologies Inc.
19.7.2021 15:44:57 CEST | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / July 19, 2021 / Aquarius Surgical Technologies Inc. (Ticker symbol - CSE:ASTI) ("ASTI" or the "Company") announces that, further to previous announcements in Press Releases dated February 22 and 25, and March 1 and 9, 2021, and as a result of the discovery of extensive fraudulent activities of Gordon Willox, a former director and officer, and other now-former executives and a now-former employee, the necessary work to complete the audit of the Annual Financial Statements and Management's Discussion & Analysis, and the related CEO and CFO Certifications for the year ended March 31, 2021, will be delayed. The Company anticipates that it will not be able to complete the filing of those documents by July 29, 2021, which is the Regulatory Filing Deadline.
The Company is working closely with its Auditors to complete the necessary review and assessments to provide reasonable assurance that the extent of fraudulent activities has been ascertained and accounted for, and that no re-statement of the Financial Statements for any prior period will be required. It is anticipated that the review and assessments will have been completed so that the Company's Audit Committee and Board will be able to review the (final draft) Audited Financial Statements and MD&A for the year ended March 31, 2021 by the week ended August 27, 2021, and thus anticipate that the Audited Financial Statements, MD&A and the related CEO and CFO Certificates will be filed immediately following approval by the Audit Committee and the Board, which is anticipated to be on or before August 27, 2021.
The Company has made an application to the Ontario Securities Commission, as its Principal Regulator, for issuance of a Management Cease Trade Order pursuant to National Policy 12-203, and intends to comply with its obligations to satisfy the provisions of the alternative information guidelines as set out in National Policy 12-203 for so long as it remains in default
The Company is not the subject of any insolvency proceeding.
The Company is taking legal action against Gordon Willox and other individuals and also including a number of corporations established by them which were utilized in the fraudulent activities, for the recovery of damages and other relief.
The Company does not anticipate that filing of the Interim Unaudited Financial Statements, MD&A and the related CEO and CFO Certificates for the First Quarter, ended June 30, 2021, which are due to be filed by August 30, 2021, will be delayed.
About Aquarius Surgical Technologies Inc.
Aquarius Surgical Technologies is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance. ASTI is focused on increasing the availability of services for patients, enhancing the quality of patient care, improving operationally efficiencies and reducing total operational costs.
For more information, please contact:
Lorne MacFarlane, CFO lornemac@eastlink.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Aquarius Surgical Technologies Inc.
View source version on accesswire.com:
https://www.accesswire.com/656050/Aquarius-Surgical-Technologies-Announces-Anticipated-Delay-in-Filing-of-Annual-Financial-Results-for-the-Year-Ended-March-31-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer10.8.2026 10:00:00 CEST | Press release
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies. Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions. As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercia
Innodata Reports Record Second Quarter 2026 Results6.8.2026 22:05:00 CEST | Press release
Revenue Up 58% Year-Over-Year, Beats Consensus by 7% Adjusted EBITDA of $25.4 Million, Beats Consensus by 50% Adjusted Gross Margin Expands to 49% Announces Planned Leadership Transition Effective September 30: Rahul Singhal to Become President and CEO, Jack Abuhoff to Become Executive Chairman NEW YORK, NY / ACCESS Newswire / August 6, 2026 / INNODATA INC. (NASDAQ:INOD) today reported results for the second quarter ended June 30, 2026. Revenue of $92.1 million, representing 58% year-over-year revenue growth. Adjusted Gross Profit of $45.4 million, representing Adjusted Gross Margin of 49%.* Adjusted EBITDA of $25.4 million, or 27.5% of revenue, an increase of $12.1 million from $13.2 million in the same period last year.* Net income of $14.4 million, or $0.43 per basic share and $0.41 per diluted share for the three-month period ended June 30, 2026, compared to net income of $7.2 million, or $0.23 per basic share and $0.20 per diluted share, in the same period last year. Cash, cash eq
Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook6.8.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / August 6, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our") reported record results for the second quarter of 2026. "Through the first half of the year, the business continues to outperform our expectations, driven by exceptional demand across our end-markets and strong conversion of our new business pipeline. Of the approximately $750 million in our pipeline, we secured initial orders that provide visibility to approximately $200 million of revenue over the next five years," said Dirkson Charles, Loar Holdings Chief Executive Officer and Executive Co-Chairman of the Board of Directors. Second Quarter 2026 Net sales of $171.6 million, up 39.4% compared to the prior year's quarter. Net income of $16.7 million, equal to the prior year's quarter. Diluted earnings per share of $0.18 compared to $0.17 for the prior year's quarter. Adjusted EBITDA of $69.4 million up 47.4% compared to the prior year's quarter. Net income
RE Royalties Announces Third Investment in Solaris Energy's Portfolio and Letter of Intent for Expanded Royalty Partnership for a Further US$62.7 Million5.8.2026 12:00:00 CEST | Press release
All amounts in US dollars unless otherwise stated. VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce a further investment of US$1 million toward the purchase of royalties on a portfolio of Solaris Energy Inc.'s ("Solaris") distributed generation ("DG") solar projects located throughout the United States. The Company also announced that it has entered into a non-binding Letter of Intent ("LOI") of up to US$67.5 million with Solaris to pursue an expanded royalty funding partnership across Solaris' current and future project pipeline. This third tranche payment brings RE Royalties' total investment in royalties over Solaris' portfolio to US$4.8 million. The Company previously funded US$3 million, as announced on January 7, 2026, followed by US$800,000 as announced on February 9, 2026. Solaris' Portfolio consists of 16 distributed generation solar projects totaling approximately 15.2
Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance5.8.2026 02:10:00 CEST | Press release
Key regulatory and quality management accreditations position the CSE-listed clean energy technology provider for accelerated commercialization and potential major enterprise contracts to manufacture and sell, residential and commercial, Zero Emissions Heating Systems using Hydrogen as a heat energy source. TORONTO, ON / ACCESS Newswire / August 4, 2026 / Kleen-Hy-Dro-Gen Inc. (the "Company") (CSE:KLN) is pleased to announce that it has officially achieved both ISO 9001:2015 Quality Management System certification and regulatory Technical Standards and Safety Authority ("TSSA") certification for its flagship product KLEEN HEAT On-Demand Hydrogen Heating System. These dual accreditations mark a major operational milestone for the Company, establishing independent third-party verification of the Company's quality assurance framework, engineering standards, and regulatory safety compliance across its Kleen Heat technology, advancing the Company's goal of safely utilizing the system in Zer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom